aTyr Pharma discovers new therapeutic intervention points harnessing innovative biology from an ancient gene family that witnessed billions of years of evolution.
We believe these new therapies will promote homeostasis in patients, the fundamental process of restoring balance in our body.
We call the proteins our scientists discovered, that we believe orchestrate homeostasis, PHYSIOCRINES:
- “Physio” for LIFE
- “Crine” for specific activity
Our founders, Paul Schimmel, Ph.D. and Xiang-Lei Yang, Ph.D., leading aminoacyl tRNA synthetase researchers at The Scripps Research Institute in San Diego, California, made significant discoveries in the field of Physiocrine Biology, along with our scientists in San Diego and Hong Kong.
By leveraging our vast patent estate of Physiocrine biology and our knowledge of rare diseases, we aim to build a proprietary pipeline of novel product candidates with the potential to treat severe, rare diseases autonomously and with partners. aTyr’s key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options.
Click here to learn more about Physiocrine Biology.